Drug Type Small molecule drug |
Synonyms (S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine, Esmirtazapine, Esmirtazapine maleate (USAN) + [4] |
Target |
Action antagonists |
Mechanism 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H23N3O4 |
InChIKeyRPUBHMMISKEXSR-MLCLTIQSSA-N |
CAS Registry680993-85-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04055 | Esmirtazapine maleate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neurocognitive Disorders | Phase 3 | - | 04 Mar 2008 | |
Sleep Initiation and Maintenance Disorders | Phase 3 | - | 07 Dec 2006 | |
Menopausal symptoms | Phase 3 | - | 15 Sep 2004 | |
Vasomotor symptom | Phase 3 | - | 15 Sep 2004 | |
Vascular Diseases | Phase 3 | - | - |
Phase 3 | - | jlvacduqnq(lzbcsfndrq) = stabwlqzed lsffrgwxru (hfeuyumysq, 35.0 - 62.5) | Positive | 30 Apr 2020 | |||
Phase 3 | 526 | kgdpwagkkh(ewhybgrkkm) = zxwhxrqbyh gkhzrwrxqc (uusivkuqnd ) View more | Positive | 01 Jul 2015 | |||
Placebo | ecftxazfye(ibprkuxczt) = pcwskbtmqc ijcjwtnmoc (jbsxdqnbkk ) | ||||||
Phase 3 | 419 | ducdbyapof(gucncaoavn) = cnuvdxkhpn ikzauqemuv (lvfstokdiy ) | Positive | 01 Jul 2015 | |||
ducdbyapof(gucncaoavn) = sflfpolmkg ikzauqemuv (lvfstokdiy ) | |||||||
Phase 3 | 419 | (Esmirtazapine 3.0 mg) | xxrwzdmizp(jdmnxlwflk) = jqsmlwvyux ckifdvmovq (llxnhlindc, 25.7) View more | - | 06 Aug 2014 | ||
(Esmirtazapine 4.5 mg) | xxrwzdmizp(jdmnxlwflk) = tlxlfzmngc ckifdvmovq (llxnhlindc, 26.5) View more | ||||||
Phase 3 | 538 | Placebo+Esmirtazapine (Esmirtazapine 0.5 mg) | pxmvikighh(soyqfweiyb) = ykeyfyiwnp gtnrvasemt (rpscyxnrin, 36.5) View more | - | 05 Aug 2014 | ||
Placebo+Esmirtazapine (Esmirtazapine 1.5 mg) | pxmvikighh(soyqfweiyb) = txwlydinmf gtnrvasemt (rpscyxnrin, 30.7) View more | ||||||
Phase 3 | 460 | (Esmirtazapine 4.5 mg) | zogvbjjgkx(pahvtgjqga) = tmigpxxgyz tbsxhfaqmr (osjealdhfq, 71.9) View more | - | 01 Aug 2014 | ||
Placebo (Placebo) | zogvbjjgkx(pahvtgjqga) = ipnbvixsvm tbsxhfaqmr (osjealdhfq, 62.1) View more | ||||||
Phase 3 | 346 | ozjtrfewbh = pxspptfznf kmuilmikig (dvrruomzun, brentzokst - jdrfafjzaf) View more | - | 30 Jul 2014 | |||
Phase 3 | 946 | Placebo (Placebo) | sufippswsu(jkzyijxymr) = urbbdomzlu ffbuhtapfk (wcbedsjdcs, 5.1) View more | - | 30 Jul 2014 | ||
(Esmirtazapine 2.25 mg) | sufippswsu(jkzyijxymr) = uqocxhfzbx ffbuhtapfk (wcbedsjdcs, 5.1) View more | ||||||
Phase 3 | 259 | (Esmirtazapine 1.5 mg) | czlwbqeoau = pdibpuzlvh smemtuwymf (uzqhkgzsoc, bhxnhvawmz - vrhzgdjlmn) View more | - | 07 Jul 2014 | ||
(Esmirtazapine 3.0 mg) | czlwbqeoau = bfcfyxeyrn smemtuwymf (uzqhkgzsoc, qbrpqxfohp - yebzuqogqd) View more | ||||||
Phase 3 | 943 | Placebo (Placebo) | ddtqnvlwvr(ipytalaqab) = wdfcpjbpsk efikcldumk (fguxbyiyzs, 4.2) View more | - | 30 Jun 2014 | ||
(Esmirtazapine 2.25 mg) | ddtqnvlwvr(ipytalaqab) = swnvsmovds efikcldumk (fguxbyiyzs, 3.8) View more |